Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution by Suleiman Al-Hammadi et al.
Al‑Hammadi et al. Exp Hematol Oncol  (2016) 5:22 
DOI 10.1186/s40164‑016‑0044‑3
RESEARCH
Effects of molecularly targeted therapies 
on murine thymus: highly selective mTOR 
inhibitors induce reversible thymic involution
Suleiman Al‑Hammadi1, Saeeda Almarzooqi2, Alia Albawardi2*  and Abdul‑Kader Souid1
Abstract 
Background: Blocking mTOR (molecular target of rapamycin) by sirolimus has been shown to suppress cellular 
respiration. The bearing of this impaired cellular bioenergetics on the mode‑of‑action of mTOR inhibitors has yet to be 
illustrated.
Methods: This study investigated in vitro effects of several molecularly‑targeted therapies on O2 consumption in 
thymic fragments from C57BL/6 mice.
Results: Thymocyte respiration (µM O2 min
−1 mg−1) was reduced by sirolimus and everolimus (p ≤ 0.007). In con‑
trast, the dual PI3K (phosphatidylinositol‑3‑kinase)/mTOR inhibitors BEZ235, GDC0980 and GSK2126458, the highly‑
selective PI3 K‑p110‑δ inhibitor idelalisib and the calcineurin inhibitor tacrolimus had no effects on thymocyte respira‑
tion. Sirolimus was administered intraperitoneally on Days 0–3 and the thymus was then examined on Days 4 and 
14. Cortex involution associated with increased cytochrome c and caspase‑3 positive cells (apoptosis) were observed 
on Day 4; these changes were resolved on Day 14 (10 days after sirolimus treatment). On Day 4, the residual thymus 
(mostly medulla) had normal cellular respiration, decreased caspase activity and increased glutathione. Intraperitoneal 
administration of sorafenib (a multikinase inhibitor) or idelalisib had no effects on thymus size.
Conclusion: Thus, the highly‑selective mTOR inhibitors imposed specific effects on the thymus, manifested by sup‑
pression of cellular respiration and induction of apoptosis.
Keywords: Thymus, Lymphocytes, Immunosuppressants, Cellular respiration, mTOR inhibitors, Sirolimus, Everolimus, 
PI3K inhibitors, Calcineurin inhibitors, Sorafenib, Idelalisib
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Background
Inhibition of mTOR by the immunosuppressant sirolimus 
(rapamycin) has been shown to decrease cellular mito-
chondrial oxygen consumption (cellular respiration) in 
Jurkat cells [1]. Exposure of the cells to 0.1 µM sirolimus 
for 30 min resulted in about 20 % decrease in cellular res-
piration. This effect was accompanied by accumulation 
of intracellular lactate and other biomarkers of anaero-
bic metabolism [1]. In another in  vitro study, inhibition 
of mTOR by 10 µM sirolimus lowered cellular respiration 
in murine heart and liver tissues by 40 % and in murine 
kidney tissue by 20  % [2]. In contrast, the calcineurin 
inhibitors tacrolimus and cyclosporine had minimum 
or no effects on cellular respiration in these organs [2]. 
These results are consistent with the known role of 
mTOR signaling in fluxing nutrients into the mitochon-
dria [3, 4].
Inhibition of cellular respiration has been reported in 
several murine organs by the dual PI3K/mTOR inhibi-
tors GSK2126458, BEZ235 and GDC0980 at drug con-
centrations ≥1  µM [5]. In contrast, the MEK inhibitor 
GSK1120212 (trametinib) and the multikinase inhibitors 
sorafenib and regorafenib had no effects on cellular respi-
ration in these organs [5].
The effects of the PI3K P110δ inhibitor idelalisib on 
cellular respiration have been also studied in  vitro in 
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several murine tissues [6]. This drug is in clinical use for 
treatment of lymphoid malignancies, with a Boxed Warn-
ing concerning its potential lung, hepatic and intestinal 
toxicities [7]. Idelalisib (10 µM) significantly lowered lung 
cellular respiration by 27 % and liver cellular respiration 
by 20 %; respiration in the intestine, thymus, spleen and 
kidney was unaffected [6]. These results are consistent 
with the known expression of P110δ in epithelial lung 
and hepatic cells [8].
It remains to be seen whether derangements in cellu-
lar bioenergetics contribute to the immunosuppressive 
activity of mTOR inhibitors. This study investigated the 
in  vitro effects of sirolimus and everolimus on O2 con-
sumption in thymic fragments from C57BL/6 mice. In 
addition, the study examined the thymus morphology 




Sirolimus (rapamycin), everolimus, tacrolimus (FK-506, 
fujimycin), idelalisib (CAL-101), BEZ235, GDC0980, 
GSK2126458, sorafenib and regorafenib were pur-
chased from MedChem Express, LLC (Princeton, NJ). 
These compounds were dissolved in dimethyl sulfoxide 
(DMSO) at 5 mg/mL and stored at −20 °C. Pd(II) com-
plex of meso-tetra-(4-sulfonatophenyl)-tetrabenzopor-
phyrin (Pd phosphor) was purchased from Porphyrin 
Products (Logan, UT); it was dissolved in dH2O and 
stored in small aliquots at −20 °C.
Monobromobimane (mBBr, m.w. 271.111) was pur-
chased from Molecular Probes (Eugene, Oregon). mBBr 
(0.1  M) was dissolved in acetonitrile and stored at 
−20  °C. Glutathione (GSH) was dissolved in dH2O and 
stored at −80 °C; its concentration was measured by Ell-
man’s reagent. GS-bimane standards and sodium meth-
ane sulfonate were prepared as previously described [9].
The pancaspase inhibitor zVAD (N-benzyloxycar-
bonyl-val-ala-asp(O-methyl)-fluoromethylketone) was 
purchased from Calbiochem (La Jolla, CA); it was dis-
solved in DMSO at 7.4 mM and stored in small aliquots 
at −20  °C. The caspase-3 substrate Ac-DEVD-AMC 
(N-acetyl-asp-glu-val-asp-7-amino-4-methylcoumarin) 
was purchased from Axxora LLC (San Diego, CA); it was 
dissolved in DMSO at 2.14 mM and stored in small ali-
quots at −20 °C. Rabbit anti-cytochrome c antibody [(H-
104): sc-7159] and rabbit anti-cleaved caspase-3 antibody 
were purchased from Santa Cruz Biotechnology, Inc. 
(Texas, USA). Glucose, HPLC-grade methanol, RPMI 
medium (Roswell Park Memorial Institute medium), 
dichloromethane, trifluoroacetic acid, methanesul-
fonic acid and remaining reagents were purchased from 
Sigma-Aldrich (St. Louis, MO).
Mice
C57BL/6 (6–8  weeks old) mice were housed at 22  °C, 
60  % humidity and 12-h light–dark cycles. They had 
ad  libitum access to standard rodent chow and filtered 
water. The study was approved from the Animal Ethics 
Committee—College of Medicine and Health Sciences 
(A29-13; in vitro assessment of the effects of nephrotoxic 
drugs and toxins on renal cellular respiration in mice).
Tissue collection and processing
Urethane (25 % w/v, 100 µL per 10 g, administered intra-
peritoneally) was used for anesthesia. The thymus was 
then quickly removed with a sterile scalpel and immersed 
in ice-cold RPMI medium saturated with 95  % O2: 5  % 
CO2. A fragment of the gland was immediately placed in 
an oxygen-measuring vial for determining the rate of cel-
lular respiration at 37 °C [10, 11]. The cellular respiration 
reaction mixture contained 1.0 mL RPMI medium, 3 µM 
Pd phosphor and 0.5 % fat-free albumin.
For the in vitro studies (Fig. 1; Table 1), thymocyte res-
piration was measured in the presence of 1.6 µL DMSO 
or 10 µM study drug. For the in vivo studies (Figs. 2, 3, 
4, 5, 6; Table 2), mice received intraperitoneal injections 
of DMSO (0.5 µL/g), sirolimus (2.5 µg/g) or other tested 
drugs (2.5  µg/g) from Day 0 to Day 3. The thymus was 
then removed on Day 4 (1  day after treatment) or Day 
14 (10  days after treatment) and processed for assess-
ment of morphological changes, immunohistochemistry 
(cytochrome c and caspase three positive cells), cellu-
lar respiration, cellular GSH and intracellular caspase 
activity.
For histology, thymic fragments were fixed in 10 % for-
malin and embedded in paraffin. Four-micron sections 
were cut and stained with hematoxylin and eosin (H&E). 
Additional sections were obtained on coated slides to 
perform cytochrome c and caspase 3 immunostains as 
previously described [6]. The immunostaining intensity 
was scored using a semi-quantitative manual method: 
strong (3+), moderate (2+), weak (1+) and negative (0), 
as previously described [10–13]. The percentage of posi-
tive cells was noted [6].
For measuring GSH, thymic fragments were incu-
bated in the dark at 25 °C in 10 mM Tris-MSA (pH 8.0) 
and 1.0  mM mBBr for 15  min. The derivatization reac-
tions were quenched with 45 µL of 70 % perchloric acid. 
The samples were then disrupted by homogenization 
and the supernatants were collected by centrifugation 
(16,300  g for 90  min) through a Microcentrifuge Filter 
(m.w. limit  =  10,000 Dalton, Sigma©). The GS-bimane 
derivatives were separated on HPLC and measured by 
fluorescence. Excitation wavelength was 390  nm and 
emission wavelength 480 nm. Solvent A was 0.1 % (v/v) 
trifluoroacetic acid/dH2O and solvent B was methanol. 
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The run time was 30  min, flow rate 1.0  mL/min and 
injection volume 5 µL. The gradient was: 0 min = 10 % 
B, 5 min = 30 % B, 8 min = 40 % B, 11 min = 50 % B, 
14 min =  60 % B, 17 min =  70 % B, 21 min =  80 % B, 
24 min 100 % B, 27 min = 10 % B, 30 min = re-inject [15].
For measuring intracellular caspase activity, thymus 
fragments were incubated at 37  °C in RPMI medium 
containing 37 µM Ac-DEVD-AMC (caspase 3 substrate) 
with and without 32  µM zVAD (pancaspase inhibi-
tor) for 55  min [14]. The tissue was then disrupted by 
homogenization and the supernatants were collected by 
centrifugation (16,300  g for 90  min) through a Micro-
centrifuge Filter (m.w. limit  =  10,000 Dalton, Sigma©). 
The filtrate was separated on HPLC (Shimadzu i-Series, 
Japan) and analyzed for the free fluorogenic AMC moiety. 
Excitation wavelength was 380  nm and emission wave-
length 460  nm. Ultrasphere IP column (4.6 ×  250  mm) 
was operated at 30 °C and flow rate of 1.0 mL/min. Sol-
vent A was dH2O and solvent B was HPLC-grade metha-







































































































Fig. 1 In vitro effects of sirolimus and everolimus on thymocyte respiration. a and c: One representative from 10 to 20 separate experiments. Each 
run represented a thymus fragment that was collected from a C57BL/6 mouse and processed immediately for measuring cellular respiration in the 
presence of 10 μM sirolimus (or everolimus) or 1.6 µL DMSO. The rate of respiration (k, μM O2 min
−1) was the negative of the slope of [O2] vs. t. The 
values of kc (μM O2 min
−1 mg−1) are shown at the bottom of each run. The lines are linear fit. b and d: Summary of all results; the horizontal lines are 
mean
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was 5 µL [6]. This analytical method measures only the 
free thiol form of glutathione (GSH), which is derivatized 
with the fluorescent agent monobromobimane (mBBr). 
Thus, the system detects only the bimane derivative of 
GSH.
Statistical analysis
Data were analyzed on SPSS statistical package (version 
19), using the nonparametric (2 independent samples) 
Mann–Whitney test.
Results
In vitro effects of the molecularly-targeted drugs on thy-
mocyte respiration Figure  1a shows one representative 
from ten separate experiments of thymocyte mitochon-
drial O2 consumption. Each run represented a thymic 
fragment that was rapidly collected from a C57BL/6 
mouse and immediately placed in the oxygen-measuring 
vial for determining the rate of cellular respiration (kc, in 
µM O2 min−1 mg−1) in the presence of 1.6 µL DMSO or 
10  µM sirolimus. Sirolimus significantly decreased the 
rate of thymocyte respiration (p = 0.007, Fig. 1b). Simi-
lar results were observed in the presence of everolimus 
(p =  0.002, Fig.  1c, d). In contrast, BEZ235, GDC0980, 
GSK2126458, idelalisib and tacrolimus had minimum or 
no effects on thymocyte respiration (Table 1). Thus, thy-
mocyte respiration is specifically targeted by the highly 
selective mTOR inhibitors (sirolimus and everolimus).
Effects of systemic administration of sirolimus on thy-
mus histology and cytochrome c and caspase 3 expres-
sions The thymus was examined on Day 4 and Day 14 
after intraperitoneal administration of 0.5  µL/g DMSO 
or 2.5  µg/g sirolimus on Days 0 to 3. On Day 4 (1  day 
after the last sirolimus treatment), the sirolimus-treated 
mice demonstrated significant thymic cortex involu-
tion (reduction in the size of the gland, p = 0.004, with 
depletion of cortical lymphocytes). There were clusters 
of epithelial cells, a feature reported in thymus involution 
as the lymphocytes are lost. There was also an increase 
in cytochrome c and caspase three positive cells, reach-
ing up to 20 % (Fig. 2a). Cytochrome c and caspase three 
expressions in DMSO-treated mice showed only rare 
(<2 %) focal positive staining in thymic cortical lympho-
cytes. Medullary positive cells were rare (Fig. 2a). On Day 
14 (10 days after the last sirolimus treatment), the histol-
ogy and cytochrome c and caspase 3 expressions in the 
sirolimus-treated mice were almost identical to those 
in the DMSO-treated mice (Fig.  2b). Thus, sirolimus 
induced cortical lymphocyte apoptosis and the cortex 
regenerated after cessation of sirolimus treatment. For 
comparison, intraperitoneal administration of the multi-
kinase inhibitor sorafenib or the p110-δ inhibitor idelal-
isib (2.5 µg/g on Days 0 to 3) had no noticeable effects on 
thymus histology or cytochrome c expression (Fig. 3).
Effects of systemic administration of sirolimus on thy-
mocyte respiration, GSH and caspase activity Mice 
received intraperitoneal injections of 0.5 µL/g DMSO or 
2.5 µg/g sirolimus on Days 0 to 3. On Day 4, the weight 
of the entire thymus was measured and fragments of the 
gland were processed for measuring cellular respiration 
(Fig.  4, one representative from three separate experi-
ments performed in duplicates), cellular GSH (Fig.  5, 
Table 1 In vitro effects of the studied drugs on thymocyte respiration
For each run, the thymus was excised from a C57BL/6 mouse, and a fragment of the gland was immediately placed in the oxygen‑measuring vial for determining the 
rate of cellular respiration in the presence of DMSO or designated drug
The values of kc are mean ± SD. The values in parentheses are number of mice (equal to number of O2 runs)
Drug concentration (µM) kc (µM O2 min
−1 mg−1) Inhibition (%) P
Sirolimus (mTOR inhibitor) 0 0.39 ± 0.10 (12) – –
10 0.29 ± 0.07 (10) 26 0.007
Everolimus (mTOR inhibitor) 0 0.46 ± 0.14 (20) – –
10 0.33 ± 0.13 (19) 28 0.002
BEZ235 (PI3 K/mTOR inhibitor) 0 0.44 ± 0.13 (12) – –
10 0.35 ± 0.16 (12) 16 0.045
GDC0980 (PI3 K/mTOR inhibitor) 0 0.48 ± 0.11 (12) – –
10 0.40 ± 0.08 (12) 17 0.089
GSK2126458 (PI3 K/mTOR inhibitor) 0 0.53 ± 0.16 (11) – –
10 0.45 ± 0.13 (11) 15 0.193
Idelalisib (P110δ inhibitor) 0 0.44 ± 0.19 (7) – –
10 0.48 ± 0.14 (8) 0 0.336
Tacrolimus (Calcineurin inhibitor) 0 0.41 ± 0.12 (12) – –
10 0.45 ± 0.10 (12) 0 0.755
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one representative from three separate experiments per-
formed in triplicates) and intracellular caspase activity 
(Fig.  6, one representative from three separate experi-
ments performed in triplicates). The results are summa-
rized in Table 2. It is worth noting that the measurements 
in sirolimus-treated mice reflected the residual thymic 
medulla and in DMSO-treated mice the entire thymic 
cortex and medulla (as shown in Fig. 2). For comparison, 
intraperitoneal administration of idelalisib (2.5  µg/g on 
Days 0 to 3) had no effects on thymus weight (Table 3).





















Fig. 2 Effects of systemic sirolimus treatment on thymus histology and immunoperoxidase staining with cytochrome c and caspase 3. Mice 
received intraperitoneal DMSO or sirolimus on Days 0–3. Thymus fragments were then stained with H&E and immunoperoxidase with anti‑
cytochrome c and caspase 3 on Day 4 (Panel a) or Day 14 (Panel b). Panel a (Day 4): DMSO (control): Normal thymus histology demonstrating darkly 
staining lymphocyte rich cortex and pale staining medulla; few (<2 %) cortical lymphocytes with positive staining for cytochrome c and caspase 
3 are present (arrow). Sirolimus: Thymic cortical involution with thinning of cortex and loss of the demarcation between the cortex and medulla; 
increased staining by cytochrome c and caspase 3 (about 20 % of the cells are positive). Panel b (Day 14): Normal thymus histology with a cortex 
rich in lymphocytes and a lymphocyte scant medulla; rare (<2 %) cortical lymphocytes with positive staining for cytochrome c are present (arrow)
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Thymic GSH (nmol mg−1) in mice treated with DMSO 
was 44 ± 14 (n = 9) and with sirolimus 82 ± 45 (n = 9), 
p =  0.019 (Table  2). For measuring thymocyte caspase 
activity, the cleavage of Ac-DEVD-AMC (a caspase-3 
substrate analogue) was measured in the presence and 
absence of the pancaspase inhibitor zVAD. The AMC 
peak area (reflecting intracellular caspase activity, in 
arbitrary unit ÷ 103 per mg) for mice treated with 
DMSO was 28 ± 15 (n = 9) and with sirolimus 12 ± 9 
(n = 9), p = 0.019 (Table 2). AMC peak areas decreased 
by ≥78 % in the presence of zVAD, confirming the cleav-
age was mediated mainly by caspases (Fig. 6). Thus, the 
sirolimus treatment resulted in a significant reduction 
in the size of the gland (p  <  0.001), increase in thymic 
GSH (p = 0.019), and decrease in thymic caspase activ-
ity (p = 0.019). The rate of thymocyte (mostly medullary 
tissue) respiration, however, did not change (p = 0.937), 
Table 2.














Fig. 3 Effects of systemic sorafenib and idelalisib treatments on thymus histology and immunoperoxidase staining with cytochrome c (Day 4). 
Mice received intraperitoneal DMSO, sorafenib or idelalisib on Days 0–3. Thymus fragments were then stained with H&E and immunoperoxidase 
with anti‑cytochrome c on Day 4. Normal thymus histology with a cortex rich in lymphocytes and a lymphocyte scant medulla; few (<2 %) cortical 
lymphocytes with positive staining for cytochrome c are present
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Discussion
This study mainly examined the effects of disrupt-
ing mTOR signals on thymocyte respiration. The 
highly-selective mTOR inhibitors, sirolimus and everoli-
mus, significantly lowered thymocyte respiration in vitro 
(Fig.  1 and Table  1). This effect was drug-specific, since 
the other studied molecularly-targeted agents did not 
exhibit similar inhibition (Table 1). This observed siroli-
mus-induced decrease in the rate of mitochondrial O2 
consumption is consistent with the known role of mTOR 
signaling in cellular metabolism, including nutrient 
transport to the mitochondria [1–4].
Lower cellular respiration implies defects in any of the 
following processes: delivering nutrients and O2 to the 
mitochondria, oxidation of reduced metabolic fuels, pas-
sage of electrons to O2 and synthesis of ATP. As previ-
ously shown for idelalisib [6], mTOR inhibitors have no 
direct effects on mitochondria isolated from murine liver. 
Thus, the observed effects (Table 1 and Fig. 1) are likely 
due to impaired lymphocyte metabolism as a result of 
blocking mTOR signaling [3, 4].
It remains unknown whether BEZ235, GDC0980, 
GSK2126458, idelalisib and tacrolimus inhibit thymo-
cyte respiration at doses higher than 10 µM. It is worth 
emphasizing that these novel molecularly targeted agents 
do not alter cellular bioenergetics at this relatively high 
concentration (10  µM). However, future studies are 
needed if any of these agents are proven to achieve clini-
cal plasma levels exceeding 10 µM.
In vivo studies, on the other hand, show marked thy-
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p=0.937
ba
Fig. 4 Thymocyte respiration in mice treated with sirolimus (Day 4). a One representative from three separate experiments. Mice received intraperi‑
toneal DMSO or sirolimus on Days 0–3. On Day 4, thymic fragments were collected and processed immediately for measuring cellular respiration. 
The rate of respiration (k, µM O2 min
−1) was the negative of the slope of [O2] vs. t. The values of kc (µM O2 min
−1 mg−1) are shown at the bottom of 
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Fig. 5 Thymocyte GSH in mice treated with sirolimus (Day 4). One 
representative from three triplicate experiments is shown. Mice 
received intraperitoneal DMSO or sirolimus on Days 0–3. On Day 4, 
thymus fragments were collected and processed immediately for 
measuring cellular GSH. The GS‑bimane derivatives (retention time, 
Rt = 7.7 min) were separated on HPLC and analyzed by fluorescence. 
The values of GSH (nmol mg−1) are shown
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This effect is due to induction of apoptosis [15], which 
depletes the cortical lymphocytes (Fig. 2a).
In this study, sirolimus treatment was from Day 0 
to Day 3. This intervention resulted in near complete 
involution of the thymic cortex (Fig. 2a). Further studies 
are needed to investigate longer duration of treatment, 
perhaps using much lower drug dosing.
Further studies are needed to address the effects of 
administering various sirolimus dosing on the thymus. 
The sirolimus dose used here (2.5 µg/g daily for 4 days) 
has been previously used for BALB/c mice of 10 weeks of 
age [16]. In one study, sirolimus administration (5.0 µg/g/
day) induced significant weight loss in old C57BL/6 mice 
[17].
This study investigated the effects of mTOR inhibitors 
on the thymus and compared them with those of other 
molecularly targeted drugs. The precise mechanism(s) by 
which mTOR inhibitors impair cellular bioenergetics and 
induce cortical lymphocyte apoptosis requires further 
investigations. Additional studies are also needed in vari-
ous disease-bearing mice.
It is also worth noting that the measurements of cellu-
lar respiration, GSH and caspase activity are performed 
immediately after excising the thymus from the medi-
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Fig. 6 Effects of systemic sirolimus treatment on thymocyte caspase activity (Day 4). One representative from three triplicate experiments is shown. 
Mice received intraperitoneal DMSO (a) or sirolimus (b) on Days 0–3. On Day 4, thymic fragments were collected and incubated with the caspase‑3 
substrate Ac‑DEVD‑AMC with and without zVAD (pancaspase inhibitor) as described in “Methods” section. The tissue homogenates were separated 
on HPLC and analyzed by fluorescence for the released AMC moieties (reflecting intracellular caspase activity, Rt = 3.44 min). The values of AMC 
peak areas (arbitrary unit ÷ 103 per mg) are shown. AMC peak areas decreased by ≥78 % in the presence of zVAD, confirming the cleavage was 
mediated mainly by caspases
Table 2 Thymus weight, caspase activity, and  GSH level 
in mice treated with sirolimus
The thymus was excised from C57BL/6 mice after intraperitoneal treatments 
with DMSO (0.5 µL/g on Days 0–3) or sirolimus (2.5 µg/g on Days 0–3). On Day 4, 
the weight of the entire gland was measured and fragments of the gland were 
processed for measuring cellular respiration, caspase activity and GSH level as 
described in “Methods” section
Expressed as µM O2 min
−1 mg−1
* Expressed as AMC peak area (in arbitrary unit ÷103) mg−1
DMSO Sirolimus P
Mouse weight on Day 0 (g) 19.8 ± 4.3 (13) 19.0 ± 4.8 (13) 0.315
Thymus weight (mg) 39.2 ± 10.2 (13) 20.7 ± 6.9 (13) <0.001
Thymocyte respiration 0.37 ± 1.0 (6) 0.36 ± 1.0 (6) 0.937
Thymocyte GSH (nmol mg−1) 44 ± 14 (9) 82 ± 45 (9) 0.019
Thymocyte caspase activity* 28 ± 15 (9) 12 ± 9 (9) 0.019
Table 3 Thymus weight in mice treated with idelalisib
Values are mean ± SD (n)
The thymus was excised from C57BL/6 mice 24 h after intraperitoneal administration of DMSO (0.5 µL/g) or idelalisib (2.5 µg/g) for 4 or 7 days
No treatment DMSO Idelalisib
Mouse weight on the day of sacrifice (g) 21.7 ± 6.4 (4) 19.6 ± 7.1 (4) p = 0.886 22.4 ± 6.7 (4) p = 0.686
Thymus weight (mg) 31.0 ± 12.0 (4) 22.5 ± 8.3 (4) p = 0.486 42.5 ± 15.5 (4) p = 0.343
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extensive tissue manipulation and will cause in vitro cas-
pase activation, mitochondrial cell death pathway ini-
tiation and GSH oxidation. Novel methods are needed in 
order to perform these measurements on different histo-
logical and/or cellular compartments (e.g., thymus cortex 
vs. medulla).
In conclusion, the results show the highly selective 
mTOR inhibitors sirolimus and everolimus significantly 
lower thymocyte respiration in  vitro. This effect is not 
observed with other studied molecularly targeted drugs 
(PI3 K/mTOR inhibitors, P110δ inhibitor and calcineurin 
inhibitor). Sirolimus treatment induces reversible thymic 
cortex involution by induction of lymphocyte apoptosis. 
The current results also support the use cellular respira-
tion as a surrogate biomarker for studying molecularly 
targeted drugs.
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